Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 11.53 USD -2.45% Market Closed
Market Cap: 629.5m USD

Wall Street
Price Targets

STOK Price Targets Summary
Stoke Therapeutics Inc

Wall Street analysts forecast STOK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STOK is 22.82 USD with a low forecast of 15.15 USD and a high forecast of 36.75 USD.

Lowest
Price Target
15.15 USD
31% Upside
Average
Price Target
22.82 USD
98% Upside
Highest
Price Target
36.75 USD
219% Upside
Stoke Therapeutics Inc Competitors:
Price Targets
300841
Chengdu Kanghua Biological Products Co Ltd
40% Upside
096530
Seegene Inc
29% Upside
ZBIO
Zenas Biopharma Inc
219% Upside
ADMA
ADMA Biologics Inc
45% Upside
ALGEN
Genoway SA
74% Upside
CRSP
CRISPR Therapeutics AG
98% Upside
FHTX
Foghorn Therapeutics Inc.
150% Upside
9926
Akeso Inc
11% Upside

Revenue
Forecast

Revenue Estimate
Stoke Therapeutics Inc

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 3 years is 3%.

N/A
Past Growth
3%
Estimated Growth
Estimates Accuracy
5%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STOK's stock price target?
Price Target
22.82 USD

According to Wall Street analysts, the average 1-year price target for STOK is 22.82 USD with a low forecast of 15.15 USD and a high forecast of 36.75 USD.

What is Stoke Therapeutics Inc's Revenue forecast?
Projected CAGR
3%

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 3 years is 3%.

Back to Top